NeuroLife Launches with Non-Invasive Neuromuscular Rehab Tech for Stroke, SCI

NeuroLife has launched as a non-invasive neurotechnology company developing wearable solutions for rehabilitation for people impacted by stroke or spinal cord injury (SCI). The company is the market-facing brand of ActivateNeuro and established through a strategic partnership with Battelle and The NeuroTech Institute (NTI).

The company’s technology is a wearable sleeve that reads electrical signals from muscles and nerves, interprets movement intent, and delivers targeted stimulation to support functional hand and arm recovery during guided therapy. The platform merges high-density neuromuscular sensing, intelligent decoding, and adaptive stimulation to translate neuromuscular signals into real-time feedback and support personalized, signal-driven rehabilitation.

The flexible platform was engineered to support applications in rehabilitation, neuromuscular analytics, and future neuro-enabled solutions.

NeuroLife completed a $2.9 million seed round with founding partners Battelle and NTI providing foundational capital, including licensing of Battelle’s NeuroLife platform technology. The company is seeking U.S. Food and Drug Administration (FDA) clearance for its wearable platform and has built a development roadmap focused on clinical validation, regulatory progression, and commercial scalability.

Comments from NeuroLife and Battelle

Jon Snyder, CEO, NeuroLife: “NeuroLife represents a focused step forward in how rehabilitation can evolve. Our goal is to develop a non-invasive platform that supports functional hand and arm use by making therapy more personalized, responsive and aligned with how the body naturally moves.”

Matt McFarland, VP of commercial strategy, Battelle: “Battelle has a long history of translating scientific innovation into real-world impact. Our collaboration with NTI and the formation of NeuroLife advances neurotechnology from foundational research into clinical and commercial development. NeuroLife brings the rigor of Battelle’s research capabilities into a platform built for clinical environments and patient impact.”